Sep 22, 2025 | Press Releases
SEATTLE, Sept. 19, 2025 /PRNewswire/ — HDT Bio Corporation, a U.S.-based clinical-stage biotechnology company advancing immune-enhancing solutions for global health, biodefense, and oncology, today announced that the U.S. Food and Drug Administration (FDA) has...
May 30, 2025 | Required Policies
IBC Meeting Minutes IBC Minutes 052225_Redacted IBC Roster IBC contacts...
Jan 24, 2025 | Press Releases
HDT Bio’s LION™ platform to support malaria vaccine development by MalarVx SEATTLE, Jan. 15, 2025 /PRNewswire/ — MalarVx, Inc., a clinical-stage vaccine company, is proud to announce a license to HDT Bio’s proprietary self-amplifying replicon RNA...
